Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination.
Antibody
BNT162b2 vaccine
CLIA
COVID-19
neutralization assay
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
01
03
2022
revised:
26
03
2022
accepted:
27
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, has caused over 460 million cases of infection and over 6 million deaths worldwide. The pandemic has called for science, technology, and innovation to provide solutions and, due to an incredible scientific and financial global effort, several prophylactic and therapeutic apparatuses such as monoclonal antibodies and vaccines were developed in less than one year to address this emergency. After SARS-CoV-2 infection, serum neutralizing antibodies are produced by B cells and studies on virus-neutralizing antibodies' kinetics are pivotal. The process of protective immunity and the duration of this kind of protection against COVID-19 remain to be clarified. We tested 136 sera from 3 groups of individuals, some of them providing multiple sequential sera (1-healthy, no previous CoV2-infected, vaccinated; 2-healthy, previous CoV2 infected, vaccinated; 3-healed, previous CoV2-infected, not vaccinated) to assess the kinetics of antibodies (Abs) neutralizing activity. We found that SARS-CoV-2 infection elicits moderate neutralizing antibody activity in most individuals; neither age nor gender appear to have any influence on Abs responses. The BNT162b2 vaccine, when administered in two doses, induces high antibodies titre endowed with potent neutralizing activity against bare SARS-CoV-2 in in vitro neutralizing assay. The residual neutralization capability and the kinetic of waning immunity were also evaluated over 9 months after the second dose in a reference group of subjects. Neutralization titre showed a decline in all subjects and the median level of S-protein IgG, over 270 days after the second vaccination dose, was below 10 AU/mL in 53% of serum tested.
Identifiants
pubmed: 35455280
pii: vaccines10040531
doi: 10.3390/vaccines10040531
pmc: PMC9024419
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione di Sardegna
ID : 2020.2197
Organisme : Associazione per l'Avanzamento della Ricerca per i Trapianti O.D.V.
ID : no number
Références
Lancet. 2021 Oct 16;398(10309):1407-1416
pubmed: 34619098
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2021 Mar 20;397(10279):1057-1058
pubmed: 33640038
Chin J Acad Radiol. 2020;3(1):4-13
pubmed: 32292880
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
J Infect Dis. 2021 Aug 2;224(3):431-434
pubmed: 34007998
PLoS One. 2022 Mar 2;17(3):e0263942
pubmed: 35235587
Signal Transduct Target Ther. 2020 Oct 13;5(1):237
pubmed: 33051445
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
JCI Insight. 2021 Nov 22;6(22):
pubmed: 34665783
Clin Case Rep. 2021 May 06;9(6):e04154
pubmed: 34178331
Clin Microbiol Infect. 2021 Dec;27(12):1845-1850
pubmed: 34329793
JAMA. 2021 Dec 7;326(21):2203-2204
pubmed: 34739043
Lancet Microbe. 2021 Jun;2(6):e240-e249
pubmed: 33778792
Vaccines (Basel). 2021 Dec 31;10(1):
pubmed: 35062724
Lancet Infect Dis. 2022 May;22(5):649-656
pubmed: 35093194
Euro Surveill. 2021 Apr;26(17):
pubmed: 33928898
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33956667
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Int J Infect Dis. 2021 Jul;108:183-186
pubmed: 34022331
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
Clin Chim Acta. 2006 Apr;366(1-2):112-29
pubmed: 16388793
Infect Agent Cancer. 2021 May 12;16(1):32
pubmed: 33980271
Clin Chim Acta. 2021 Aug;519:60-63
pubmed: 33857476
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Clin Exp Med. 2021 Nov 5;:
pubmed: 34741188
Clin Chem Lab Med. 2021 Apr 14;59(8):1444-1452
pubmed: 33855843
Clin Chem Lab Med. 2021 Dec 16;60(3):456-463
pubmed: 34911170
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508